RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON
About This Scorecard
A literature scorecard built on one discipline: say what the evidence actually supports, and say plainly when it doesn't support much yet.
What the scorecard covers
Best Peptide grades the evidence behind five research peptides that are often discussed together but sit at very different points on the evidence ladder: CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, with semaglutide as the lead compound on the strength of its trial record. The scorecard exists because research-peptide marketing routinely treats 'published research exists' as if it meant 'this works and is safe,' when a single eleven-person pharmacokinetic study and a 17,000-participant randomized outcome trial are not remotely the same kind of evidence, even though both technically count as published research.
The organizing idea is to grade evidence honestly across categories that rarely get compared side by side: a growth-hormone-releasing-hormone analog, a ghrelin-receptor secretagogue, an anti-inflammatory tripeptide, an investigational metabolic triple-agonist, and one fully approved metabolic drug. Read together, the differences in evidence maturity are far harder to miss than they are in any single compound's marketing.
How the scorecard is kept
Three habits govern the site. First, every factual claim ties to a specific citation on the references page — peer-reviewed journal articles and clinical-trial publications, with DOIs and PubMed links — and each compound page separates primary research from review-level synthesis. Second, findings are reported in the species and population actually studied: a rat pharmacology result is labeled a rat result; an eleven-person study is labeled small; a Phase 2 trial is labeled Phase 2, not quietly upgraded to proven. Third, where the published record is thin or absent in humans — as with KPV — the scorecard says so directly rather than filling the gap with confident-sounding mechanism talk borrowed from animal data.
Community-reported experience appears where it exists, because it is genuinely part of how these compounds are discussed, but every such paragraph is marked as anecdotal and unverified, and none is presented as though it came from a controlled trial.
The boundaries
Best Peptide is not a pharmacy, clinic, telehealth service, or seller of any kind. It sells, sources, and brokers no compound, and it holds no affiliate or referral tie to any research-chemical supplier, pharmaceutical company, or telehealth provider. It does not diagnose, prescribe, or name a dose, schedule, or route for any person, for any of the five compounds covered here.
Semaglutide is an approved prescription medicine available only through licensed medical providers. Retatrutide is investigational and not legally available outside registered clinical trials. CJC-1295, ipamorelin, and KPV are, by regulatory status, research chemicals with no approved human indication anywhere; nothing here should be read as encouragement to obtain or use any of them outside a legitimate research or clinical context. A reader seeking medical guidance should consult a licensed clinician. Editorial correspondence on citations, corrections, or newly published research can go to the contact page.